its like the market thinks this is a drug to treat apnea. it is another weight loss drug with the same mechanism as ozempic. that through weight loss there is a reduction in apnea. everyone already knows this. interesting to note, was when they used drug and cpap there was further decrease in apnea. some people will come off their cpap with weight loss. the company research is showing that these drugs are bringing more potential customers into the health care system and subsequently into the cpap pipeline than what is currently coming off their machines through weight loss.
this could present another trading opportunity.
RMD Price at posting:
$28.88 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)